The PAR-binding chromatin remodeler ALC1, which was recently identified as an actor of PARPi toxicity in HR-deficient cells through the accumulation of PARP trapping and stalled replication forks [102], is a novel potential therapeutic target in HR-deficient breast cancers. Here, PARP1 is linked to breast carcinoma.